Microbioz India December 2017

Page 1









38

38

30 32

14 24

Cover Story 14

Product Launches 34

This time with a focus on Nepal Lab Expo. The edition starts with a Pre-Show Report on the Nepal Lab Expo, an Exhibition & Conference on Laboratory, Analytical, Medical & Biotechnology Instruments from 14th to 16th December 2017 at BhrikutiMandap Exhibition Hall, Kathmandu.

This is not all, do not forget to read a product launch by Ami Polumer Pvt Ltd titled “Imaseal® - Silicone Inflatable Seals and Gaskets” and other business news.

Laboratory Business 30 Grab interesting business news collected from the world of Laboratory and Technology.

Featured article 16 You can find a featured article titled ‘Considerations for Extraction, Stabilization and Quantification by PCR for Sensitive Sample Such as RNA’ authored by Andrew J. Birnie, Ph.D., Global Life Sciences Product Manager, Cole-Parmer India Pvt Ltd

Editor’s Pick 24 An Editor’s Pick titled ‘Anticancer properties of Nelumbo nucifera (LOTUS)’ authored by Manisha Bansal, Banasthali University, Jaipur, Rajasthan, India

Upcoming Events 44 We have compiled a list of Upcoming Largest Laboratory, Medical & Pharma Events and Trade Shows

9




ear friends, the year is going to end soon with a just few days left to complete unfinished tasks and add on more victories. It was a great year for MICROBIOZ INDIA full of challenges and achievements and we wholeheartedly thank our readers for their love and support all throughout the year and we look forward to the same support from you for the upcoming year too in the journey of MICROBIOZ INDIA. With extreme pleasure, I hereby present yet another exclusive event special edition for my esteemed readers. This time with a focus on Nepal Lab Expo. The edition starts with a Pre-Show Report on the Nepal Lab Expo, an Exhibition & Conference on Laboratory, Analytical, Medical & Biotechnology Instruments from 14th to 16th December 2017 at Bhrikuti Mandap Exhibition Hall, Kathmandu. Further, you can find a featured article titled ‘Considerations for Extraction, Stabilization and Quantification by PCR for Sensitive Sample Such as RNA’ authored by Andrew J. Birnie, Ph.D., Global Life Sciences Product Manager, Cole-Parmer India Pvt Ltd and an Editor’s Pick titled ‘Anticancer properties of Nelumbo nucifera(LOTUS)’ authored by Manisha Bansal, Banasthali University, Jaipur, Rajasthan, India This is not all, do not forget to read a product launch by Ami Polymer Pvt Ltd titled “Imaseal® - Silicone Inflatable Seals and Gaskets” and other business news. I hope you have a good read. As we close this edition, we would like to wish our readers an AMAZING NEW YEAR 2018. Hope this year brings you to the moments full of happiness and achievements. The magazine is incomplete without the love and support of the valuable readers. Your valuable feedback and suggestions are always welcome as they help us come with better content each time. For any further value addition, kindly write to us at editor@microbiozindia.com.



EVENT REPORT

Nepal Lab: 2017 2nd International Exhibition & Conference on Lab, Analytical & Biotechnology Instruments

e are excited to host 2nd NEPAL LAB EXPO – Exhibition & Conference on Laboratory, Analytical, Medical & Biotechnology Instruments from 14th to 16th December 2017 at Bhrikuti Mandap Exhibition Hall, Kathmandu.

W

NEPAL LAB is the largest laboratory event in the country to increase overall growth of laboratory & analytical sector in the region. Expo will provide a platform to worldwide trade manufacturers and local suppliers to connect, network, brand and business with local trade professionals. This is a wonderful opportunity to all to come and experience the Nepal market and find business opportunities in the region. NEPAL LAB covers the whole range of laboratory & analytical techniques, instruments, lab chemicals, educational lab instruments, biotechnology, life science, medical science, microscopes, laboratory furnishing, lab safety facilities, environmental and pollution control,

measuring & testing equipment’s, lab services, laboratory consumables etc. We are inviting scientists, pathologists, lab directors, pharmaceutical lab professionals, food technologists, lab technicians, government officials, trade suppliers, purchase managers and every one related to lab. We are expecting 5000+ trade visitors in the show in three days. We are also planning of various workshops concurrently with the show. Conference during the exhibition covers different topics related to laboratory and analytical techniques, laboratory accreditation and latest diagnostic techniques. The conference is useful and knowledge platform for pharmaceutical, food, material testing, diagnostic and research laboratories. There are 200+ manufacturers, importers and wholesalers are participating in this mega expo including more than 500+ top brands from India and globally. We are sure all the exhibitors will get good response in term of business and networking. This event would provide an

excellent opportunity to every participant to showcase its strength to professionals in the region. The expo will give much needed boost to laboratory industry in the country by not only providing opportunities to enter into strategic alliances and partnerships to source products, explore new market and networking with worldwide manufacturers and importers. Trade professionals in the exhibition will learn, study, experience latest technology, new product launch and future in the field. We hope and expect the 2017 event along with the workshops will not only give a new boost to the industry in Nepal by providing many business opportunities but will also inspire a number of ideas, research avenues, findings and synergies, in this event. Mail: info@sdpromomedia.com

14



FEATURED ARTICLE

Considerations for Extraction, Stabilization and Quantification By PCR for Sensitive Sample Such as RNA By Andrew J. Birnie, Ph.D., Global Life Sciences Product Manager, Cole-Parmer

Introduction he accessibility of PCR and qPCR systems has increased to where they are almost considered a commodity product today. This is certainly the case for endpoint PCR systems and some qPCR units also allowing researchers to carry out gene expression analysis more conveniently and quickly. This accessibility has been an innovative development in the community and will continue to move research forward for years to come.

T

There have been concerns with regards to reverse transcriptase (RT-PCR) and real-time RT-PCR analysis of sensitive sample types such as RNA due to the stability of the same during process and storage. Just how much impact this has had upon the results may go unknown. Recent advances into techniques such as digital PCR and new advances in extraction stabilization systems have sought to address some of these concerns.

Extraction In theory, the extraction process is a relatively trivial matter: disrupt the sample’s cellular integrity and collect the

Quantification by PCR has become more accessible but care must be taken when choosing the correct unit for the correct application. released nucleic acids. However, it is never that simple. Multiple factors must be addressed. When performing any nucleic acid extraction (especially RNA), stability and integrity of that extract must be considered. Samples being extracted in remote field studies must also take into consideration logistical concerns such as power supply, temperature control, availability to equipment, and shipping if

samples are not to be tested onsite immediately. Another concern with general tissue extracts is the heterogeneous mixture of cell states and types being sampled or extracted from. The result of performing an extraction from a mixed population of cell is apparent and will result in a gene expression profile which represents, at best, an average for that cell population. When considering tissue extracts in diseased or infected sample against wildtype expression, care must be taken to

16



FEATURED ARTICLE limit the number of wild-type cells in the diseased sample as these may affect the expression profile, or the wild-type cells

Protection from degradation for RNA extractions is an important and sometimes overlooked aspect of gene expression profiling. themselves may have an altered gene expression due to proximity to a diseased or infected cell. This has previously been documented when bulk extracts are compared with laser microdissected cells. Due to the above, an ability to extract smaller volumes reliably and minimize loss of target material, or in some instances perform expression profiles on one specific cell, has driven the development of single-cell gene expression analysis kits. The single-cell extraction and gene expression kits typically have few steps and contain reagents for the sample extraction, reverse transcription, a means to inhibit cell-sourced RNase and the qPCR components, making it a rapid system. Due to the small number of targets, the extraction process can have an impact upon the results of the realtime RT-PCR which must be performed quickly. Contaminating DNA can be removed with the inclusion of a DNase treatment step, typical of most RNA extraction systems. The advantages of such kits are apparent as there are limited chances to lose sample, and the

target can be the exact cell type that should be profiled. A limitation of such kits could be their apparent high cost per extraction, but the possible advantages of gene profiling experiments from one cell cannot be overlooked.

the Arcis Sample Prep Kit is compatible with common applications such as PCR (end-point, RT-qPCR), real-time PCR, isothermal amplification (LAMP), sequencing (Sanger, Pyro and Next Generation) and genetic profiling (electrophoresis).

Other more standard kits, such as silica column-based extraction systems that typically need more starting material than single-cell kits, require multiple liquid handling steps and washes, and require additional heating equipment and centrifugation. These type of extraction systems often require a specific kit for a sample type or to extract either DNA or RNA. Samples once extracted may be subject to degradation unless stored and treated correctly, especially RNA extractions. These kits are more commonly adopted, perhaps in part to the familiarity of the protocols, performance and the cost per extraction can be less than some other approaches.

This novel Arcis Sample Prep Kit relies upon smaller volumes of starting material than some column-based systems and, unlike other products, can extract both DNA and RNA at the same time removing the need and cost associated with having separate DNA and RNA extraction kits. The system is not enzymatic and has an added benefit of stabilizing samples at ambient temperatures, both DNA and RNA, for extended periods of time with minimal impact on Cqs or sample integrity.

A well-documented issue which arose from publications in 1998 and 2002 in which an apparent association of the MMR vaccine and bowel inflammation with developmental disorders in children caused a number of incidences where children were not immunized. Development of new extraction systems has continued and recently a novel extraction system has been introduced to the market requiring only two steps, limiting the manual pipetting error which can occur when multiple pipetting steps are required, and can be completed in three minutes at room temperature. The Arcis Sample Prep Kit provides high-quality, PCR-ready templates without the need for additional laboratory equipment such as centrifuges or hot blocks that are required with other approaches. The simplified workflow has maintained high yields and

Stability data currently shows 100+ days for DNA and 6 days for RNA when stored in the Arcis Sample Prep Kit at ambient temperatures. Developments such as the Arcis Sample Prep Kit could enable more robust analysis of transcript levels, especially for those assays which are targeting low target expression, by limiting the degradation common in extracted RNA targets as well as simplify the process of transporting temperaturesensitive nucleic acids between sites as no cold chain logistics would be required in most cases.

Techniques qPCR Controls are key in any scientific approach and developments in the PCR/qPCR field have attempted to limit spurious amplicon production which negatively impacts upon the target experiment’s efficiencies. Polymerases have become better immobilized prior to PCR and primer and probe developments have also helped reduce inappropriate binding and amplification. Buffer formulation for polymerases has also enhanced the performance of polymerases and made them more specific, sensitive and tolerant to difficult templates.

18



FEATURED ARTICLE The results of poorly controlled qPCR have been well documented and can have significant impacts on the community and beyond. A well-documented issue which arose from publications in 1998 and 2002 in which an apparent association of the MMR vaccine and bowel inflammation with developmental disorders in children caused a number of incidences where children were not immunized. A number of court cases soon followed.

DNA or RNA transcript copy number as accurately as possible. dPCR reaction components will be similar to qPCR and often use hydrolysis probes like qPCR. A differentiator from qPCR is that dPCR does not reference an internal control or standard curve instead counting the exact transcript number in the assay. This can increase the accuracy of the measurement when compared to qPCR. dPCR setup differs from qPCR in that

In these two papers, it was shown that the qPCR data was not correctly controlled and standard operating procedures were not followed, data analysis was incorrect and there were issues associated with the RT steps before the qPCR. The combined effect caused incorrect conclusions. This and other cases resulted in scientists in the community generating the MIQE (Minimum Information for Publication of Quantitative Real-Time PCR Experiments) guidelines. The goal was to develop guidelines to promote laboratory consistency, help ensure the integrity of scientific literature, and increase transparency of experiments. These guidelines also provide information necessary for providing the minimum information for evaluating and reporting qPCR experiments. System (PCR hardware) effects must also not be overlooked when carrying out sensitive assays. In general terms, variability across a PCR/qPCR systems thermal block is best limited to as little as possible as variability in temperature control may impact the result. Ideally systems with high uniformity should be used to limit data variability. Systems such as the Eco/Prime Pro from ColeParmer which utilise a liquid filled block to deliver best in class uniformity would be examples of such systems.

Digital PCR Digital PCR (dPCR) was first developed in the mid-90s and recently has grown in popularity due to investment from some of the larger manufacturers. The technique was developed to quantify

when high sensitivity is required compared to other techniques. Conclusion There are several issues to be addressed when attempting to accurately define the transcript level of a specific target, not all of which have been covered here. Careful selection of an extraction system that helps stabilize and protect targets, especially RNA, or which allows for immediate analysis must be considered. The systems used after extraction must also be considered and careful selection regarding system accuracy may also factor into the decision.

About the Author Andrew J. Birnie, Ph.D., is the global life sciences product manager for Cole-Parmer. He gained a Ph.D. in Veterinary Parasitology in 2008 from the University of Glasgow and following some time in research moved to a commercial role within the molecular biology sector. View Cole-Parmer’s selection of PCR and RTPCR systems on ColeParmer.in Questions? Get instant answers, contact Cole-Parmer application specialist at 02261394444 / response@coleparmer.in

Andrew J. Birnie, Ph.D., is the global life sciences product manager for Cole-Parmer after the similar reaction components are assembled, one large reaction mixture will then be partitioned into approximately 20,000 smaller reaction vessels by creating oil droplets within the reaction well. Each oil droplet has within it the required components for PCR to occur, and after amplification each droplet is then scored for presence or absence of the specific target being investigated and a profile for that target generated. dPCR could still suffer from the issues previously discussed with regards to extraction but will have the advantage of scoring exact transcript number rather than determining this by plotting unknowns against a standard curve. dPCR has also been shown to have advantages in multiplex environments or

About Cole-Parmer With more than 60 years of experience, Cole-Parmer is a global leader in supplying fluid handling, life science, and general laboratory products, instrumentation, and equipment to the Biotech, Chemical, Academics, Environmental, Food, Industrial Manufacturing, and Print industries. Offering a wide selection of products and instrumentation, Cole-Parmer works with R&D, pilot plant and production, specializing in providing scaleup assistance. With a mix of proprietary products and strategic partnering with leading manufacturers, Cole-Parmer’s business is highly diversified across a spectrum of products, consumables, services and solutions.

For more details, please contact: Cole-Parmer India Pvt. Ltd. Tel: +91-22-61394444 response@coleparmer.in www.coleparmer.in

20



GUEST POST

India’s First E-Commerce Dedicated for Laboratory, Life Science and Diagnostic Products Need lab products? Visit www.biomall.in now! Or Contact us: info@biomall.in / +91-22-66918891

Biomall.in (www.biomall.in) is one of the leading e-commerce portal based in India. It is dedicated to supply an extensive range of laboratory requirements and scientific products to researchers from India, and rest part of the world. The portal offers 200,000+ products listed from 90+ brands catered for Chemistry, Microbiology, Cell Culture, Chromatography, Genetics, Proteomics Research. Biomall also runs a Science blog (www.biomall.in/blog) which is regularly updated with articles on latest research in life sciences thus helping to promote scientific temperament in the community. A typical procedure for purchase of research products in India include multiple quotations, raising an indent, generating purchase order, high lead times for delivery and finally a delayed payment to the supplier stretching the sale process easily to a few months! With Biomall, the whole process gets reduced from few months to a few days (and just a few clicks), benefitting both the buyer and the seller. The buyer can now get the products from various brands on a single platform rather than approaching different vendors for each. The buyer also gets directly connected to the manufacturer and gets the best deal/offer with a real-time stock availability. Through the online system, Biomall has supplied lab products to various states in India such as Jammu & Kashmir, Himachal Pradesh, Punjab, Bihar, Gujarat, Maharashtra, Goa, Karnataka, Kerala as well as remote areas in Mizoram, Assam, West Bengal. Soon, awareness for the benefits of online purchases is expected to spread the business in all corners of the country.

Biomall.in Connects Suppliers from India to Buyers across the World The manufacturer can directly promote their products across the globe to the end customers by simply listing their products on our platform. It is remarkably advantageous for the newer brands to promote their products at par with the leading companies in the Industry. Sellers can liquidate their stock inventory by uploading their products on Biomall.in and providing competitive offers. Through its online platform & digital marketing services, Biomall has been able to connect Indian manufacturers like Research-Lab-FineChemicals, Micromaster, Avra Synthesis & Biosystems Company to a much larger audience across India as well as overseas. In last few months, Biomall has been able to supply Indian manufactured products to research labs,

Diagnostic labs & hospitals based in foreign countries like Dubai, Italy, Kenya, South Africa, and South Korea. It has also promoted Germany based brand – Waldner, in the scientific market of India. Biomall aims to digitally connect every supplier to the scientific community and creating a win-win situation for everyone involved in the business. Biomall platform is very useful for new lab setups, as everything from lab furniture to equipment and consumables can be procured from the vast network of its suppliers. Best deals, easy ordering, faster service, better connectivity (Chat, Email, Call), are a few of its highlights. More can be realized as one becomes a member of the Biomall family.

22



EDITOR’S PICK

Anticancer properties of Nelumbo nucifera (LOTUS): A Review It has been previously reported that Nelumbo nucifera has anti-proliferative activity and it inhibits the proliferation of various different types of cancer like gastric cancer, human melanoma, prostate, lung cancer, breast cancer etc. Lotus has those phytoconstituents that are helpful in stimulating apoptosis and inhibiting pathways which are responsible for the proliferation of cancer cells. By: Manisha Bansal, M.Sc. Biotechnology, Email Id: manishabansal467@gmail.com otus (Nelumbo Nucifera) is a plant that has many beneficial properties that are recently used to prepare herbal drugs and to treat various disorders. In this review article, we have focused on the anticancer properties and various other biomedical properties of the Nelumbo nucifera. It has been previously reported that Nelumbo nucifera has anti-proliferative activity and it inhibits the proliferation of various different types of cancer like gastric cancer, human melanoma, prostate, lung cancer, breast cancer etc. lotus is having those phytoconstituents that are helpful in stimulating apoptosis and inhibiting pathways which are responsible for the proliferation of cancer cells. It is extensively studied that sacred lotus is having a large number of pharmacological properties and these properties are present because of phytochemicals that are present in different parts of the lotus plant. Various extracts in different solvents have been reported to be responsible for anticancer and other biomedical properties of the lotus plant. The present review is an effort to unite the anticancer properties of lotus plant and its studied pathways yet.

L

Keywords: Biomedical properties

Lotus, Anticancer, application, beneficial

Introduction

Lotus (Nelumbo nucifera) is also known as a sacred lotus or Indian lotus. It is easily available throughout Australia and Asia. It is known by various names like ‘Kamala’ and ‘Padma’. It is a well-known aquatic species of plant that requires full sun to survive and a good amount of space as well (1). Lotus is an edible as well as the medicinally important plant. Nelumbo nucifera is a well-known ornamental plant that is erect aquatic herb which is having beautiful leathery soft leaves about 20 inches in diameter. The flower of the lotus is pink or white in color and has a yellow centre. The roots of the flower are present down inside the muddy water. The fruiting and flowering time of Nelumbo nucifera is from March to December basically. It is

found in various ponds, lakes and The propagation division of seeds 12,13)

places like freshwater muddy water as well. of lotus is through or by rhizomes.(7,10,

Cancer is an ailment that is responsible for uncontrolled cell proliferation and differentiation, cell death and destruction of the organ in which cancer cells invade. As cancer incidences are increasing day by day, various treatments are available like chemotherapy, a treatment of cancer cells using drugs, or through radiation therapies. But these methods have a large number of side effects. Lotus is a natural god gift that is helpful in treating cancer (3, 4, 5, 6, 7 ). We just need to pay attention towards its


24


EDITOR’S PICK pharmacological properties so that the ill effects produced by chemical drugs will be reduced and cancer patients can be treated well. There are different types of cancers. Sameer et al. reported the five histological classifications of cancer that are:(12)  Carcinoma  Sarcoma  Myeloma  Leukemia  Lymphoma They have also stated that cancer drugs show the same mechanism of action approximately by blocking the growth of living cells. But by which the drug is performing the function is different on the basis of cellular function and cell target. The organ or tissue on which the drug is acting and the functioning of that organ affect the activity of anticancer drugs on the body. Lotus (Nelumbo nucifera) is known to have anticancer properties and it is widely studied as well. The anticancer properties are generated due to the presence of different phytochemicals like aporphine alkaloids (14) which are reported that is responsible for anti-proliferative activity produce by lotus.

Anticancer properties of Lotus Sasikumar et al. have reported that different parts of the lotus plant possess different activities and effects which are highly useful for the mankind health. The reported pharmacological properties are anti-diabetic, anti-inflammatory, antipyretic, Nootropic, anti-estrogenic, effects on lipids and obesity, anti-platelet activity, cytoprotective effects, antianalgesic, anti-diarrheal, immunodulatory effects, hepatoprotective effects, antidepressant activity, anti-allergic effect, antiarrhythmic effect, anti-fertility effects and various other. (2, 9, 11, 15, 16) Herbal drugs are in trends nowadays and various herbal drugs are prepared using lotus plant parts. Various different extracts have been prepared using different parts of the lotus plant and it has been reported that different extracts are responsible for different activities.

From ancient times lotus plant parts are used as food additives and food supplements especially in countries like Egypt, Middle East and China. The Nelumbo nucifera is proved to be having various beneficial effects on mankind. Various phytoconstituents have been derived from different parts of the lotus plant parts like stem, leaves, roots, stamen, rhizomes, stems and fruits. Various phytoconstituents that have been derived from different parts of lotus which are alkaloids, flavonoids, glycosides, saponins etc. The alkaloids reported are Nuciferine, Neferine (41), Lotusine, Isoliensinine, Quercitin, Isoquercitin and various other aporphiealkaloids(2,3,14, 25,26,27). It is also reported that seeds of N. Nucifera contain 2-3% oil which constituted of myristic, palmitic, oleic and linoleic acid. These phytochemicals are responsible for various different activities that are named above (20, 21, 22, 23, 24, 29). It is reported that different extracts prepared using different parts of lotus plant using different solvents like methanol, ethanol, and aqueous extract have the activities that are traditionally useful to treat many types of conditions like diarrhea, poor digestion, fever, insomnia and abnormal bleeding, hematemesis, hematuria, hyperlipidemia and effects on lipids and obesity. This review article explained the anticancer properties of lotus (37, 38, 39) Paramasivanpoornima et al. in 2014 have reported that neferine (alkaloid) is responsible for inhibiting lung cancer cell growth by activating MAP kinase pathway and arresting cell cycle.(13) The seeds of the Nelumbo nucifera are very useful. It is widely used in sacred places and also as food additives. Seeds of Lotus consist of a large number of phytoconstituents and secondary metabolites which are responsible for it specific properties that it possess. Pulokmukherjee et al. in May 2009 and Keshav raj pander et al. in October 2015 reported the list of phytocontituents or secondary metabolites present in lotus seeds. The different alkaloid phytoconstituents that they have been reported are; Dauricine, pronuciferine, D(-)-3’bromo-O-methyl-armepavine, procyanidin, gallicacid,nuciferine,

roemerine, lotus, armepavine, D-1,2,3,4tetrahydro-6-methoxy-1-(pmethoxybenzyl)-2-methyl-7isoquinolinol etc.(8) These phytochemicals are responsible for different functions like antiproliferative activity, antioxidant properties, hepatoprotective activity, antiinflammatory activity, anti-arrhymic activity and ant fibrosis activity of lotus seeds (19,28, 40) The focus of this review article is anticancer properties of different parts of Nelumbo Nucifera. So further we will consider anticancer properties of lotus seeds.

Lung cancer It has been studied that ‘Neferine’, an alkaloid present in the lotus seed is responsible for inhibiting lung cancer by activation of MAPK pathway and arresting cell cycle. In 2013, Paramasivan Poornima et al. have been reported that the proliferation of human cell line, H441, H520 and H661 (Non small lung cancer cells) has decreased as the dose and time increased. They have also reported the novel mechanism of reactive oxygen species (ROS) induced cell death by having the properties which are responsible for causing apoptosis. They concluded that the inhibition of lung cancer cells occurred in dosedependent manner.

Peripheral blood mononuclear cell proliferation In November 2013, chin pengliu et al. has been studied that inhibition of Peripheral blood mononuclear cells (PBMC) proliferation which are activated using phyto-haemaglutinin (PHA) occurred through ethanolic extract of lotus and it has also been reported that the mechanism behind the inhibition is the suppression of cell cycle progression at G0/G1 phase and cytokine gene expression (18,30). In May 2007, chin pengliu et al. have isolated S-Armepavine from lotus seeds and reported that this is responsible in inhibiting the PHA activated

26



EDITOR’S PICK PBMC Proliferation by inhibiting interleukin-2 and Interferon-γ. It is also observed that this alkaloid is responsible for improvement of autoimmune disease in mice. The mechanism behind this suppression or inhibition is blockage of T-cell kinase and phospholipaseCγwhich are inducible membrane effectors by phosphatidylinositol3kinase-dependent manner (31, 32).

Smooth muscle cell proliferation Isoliensinine, a bisbenzylisoquinoline alkaloid derived from lotus seeds is studied by Xiao JH et al., in year 2006 and they have reported that angiotensin II(increases proliferation by 42%) activated porcine coronary arterial smooth muscle cells (CASMCs) inhibition take place due to presence of this alkaloid and they have proved their finding of inhibition by using MTT assay, immunohistochemistry and Western blotting (33,34)

Breast cancer Isoliensinine, an alkaloid isolated from lotus seed is known to be responsible in inhibition of various different kinds of cancer and having great anti-proliferative activity. It was studied by Xiyu Zhang et al. in year 2015 that isoliensinine is responsible for inhibiting triple negative breast cancer cells by generating ROS and activating p38 MAPK/JNK{35)

Gasticcancer and liver cancer In October 2016 yafengzheng et al. has been studied the invivo and invitro effects of the hot water soluble polysaccharide(LSPS) isolated from lotus seeds is having inhibitory effects against human liver cancer HuH7 cells, mouse gastric cancer MFC cells and mouse hepatocarcinoma H22 cells. In in-vivo studies they have found that LSPS is having least cytotoxic effect against mouse MFC cells but are inhibitory for both liver cells. So they have concluded that LSPS is more effective for

hepatoma cells. In in-vitro studies they have found that there is no reduction in the mouse body weight LSPS is administered orally to mouse in comparison with the CTX treated mouse in which due to toxicity the reduction in weigh take place. They have suggested that LSPS leads to immune system activation and having least side effects as compared to CTX (33). Paramasivan Poornima et al. in year 2012 have been reported that the proliferation of human liver cancer cell line HeoG2 cells proliferation has been decreased as the dose and time increased. They have also reported the novel mechanism of reactive oxygen species (ROS) induced cell death with having the properties which are responsible for causing apoptosis. They concluded that the inhibition of liver cancer cells occurred in dose dependent manner (36).

Conclusion In conclusion, this review represents that lotus is primitively and recently used as anticancer agent but due to its low activity on human its usage is decreasing eventually. But as tested by various researchers lotus is having various such phytoconstituents which are responsible for its use as anticancer agent.

References 1. Nishkruti R Mehta et al., Nelumbo nucifera (Lotus): A Review on Ethanobotany, Phytochemistry and Pharmacology, Indian Journal of Pharmaceutical and Biological Research (IJPBR), 2013;1(4):152-167 2. SasikumarDhanarasu and Awdah Al-Hazimi, PHYTOCHEMISTRY, PHARMACOLOGICAL AND THERAPEUTIC APPLICATIONS OF NELUMBO NUCIFERA, Asian Journal of Phytomedicine and Clinical Research. 1(2), 2013, 123 - 136., Review Article ISSN: 2321 – 0915 3. Pulokmukherjee et al. , The sacred lotus (Nelumbo nucifera) - phytochemical and therapeutic profile, J Pharm Pharmacol. 2009 Apr; 61(4):407-22. doi: 10.1211/jpp/61.04.0001. 4. yasribqurishi et al., Isolation and antiproliferative activity of Lotus corniculatuslectin towards human tumour cell lines, phytomedicine international journal of

Phytotherapy and phytopharmacology, Volume 21, Issue 1, 15 December 2013, Pages 30–38 5. SongheeJeon et al., Lotus (Nelumbo nuficera) flower essential oil increased melanogenesis in normal human melanocytes, EXPERIMENTAL and MOLECULAR MEDICINE, Vol. 41, No. 7, 517-524, July 2009 6. Su-Yeon Kim and Gap-Soon Moon, Photoprotective Effect of Lotus (Nelumbo nuciferaGaertn.) Seed Tea against UVB Irradiation, Prev. Nutr. Food Sci. 2015;20(3):162-168 (http://dx.doi.org/10.3746/pnf.2015.20.3.162) 7. Partha P Majumder et al., Genome and Evolution of the Sacred Lotus, Indian Journal of History of Science, 51.2.2 (2016) 351-353, DOI: 10.16943/ijhs/2016/v51i2.2/48447 8. Keshav Raj Paudel and NishaPanth, Phytochemical Profile and Biological Activity of Nelumbo nucifera, Hindawi Publishing Corporation, Evidence-Based Complementary and Alternative Medicine,Volume 2015, Article ID 789124, 16 pages( http://dx.doi.org/10.1155/2015/789124 ) 9. Arjun Pandian et al., Phytochemical analysis and anticancer activity of Nelumbo nucifera extracts, J. Acad. Indus. Res. Vol. 1(2) July 2012 10. Xianbao Deng et al. , Analysis of Isoquinoline Alkaloid Composition and WoundInduced Variation in Nelumbo Using HPLCMS/MS, Journal of agricultural and food chemistry, 2016, 64,1130-1136 11. Subzar Ahmad Sheikh, Ethno-medicinal uses and pharmacological activities of lotus (Nelumbo nucifera), Journal of Medicinal Plants Studies 2014;2(6):42-46 12. Sameer Mehndiratta et al., A Review on Plants a useful source of anti-cancer drugs, ournal of Pharmacy Research 2011,4(1),264-271 13. PoornimaParamasivan et al.,Neferine, an alkaloid from lotus seed embryo, inhibits human lung cancer cell growth by MAPK activation and cell cycle arrest, Biofactors. 2014 Jan-Feb; 40(1):121-31. doi: 10.1002/biof.1115.. 14. Chi-Ming Liu, Chiu-Li Kao, Hui-Ming Wu, Wei-Jen Li , Cheng-TsungHuang,Hsing-Tan Li, and Chung-Yi Chen, Antioxidant and Anticancer Aporphine Alkaloids from theLeaves of NelumbonuciferaGaertn. cv. Rosa-plena, Molecules2014, 19, 17829-17838; doi:10.3390/molecules191117829 15. Yafeng Zheng et al., Cytotoxic, Antitumor and Immunomodulatory Effects of the WaterSoluble Polysaccharides from Lotus (Nelumbo nuciferaGaertn.) Seeds, Molecules2016, 21(11), 1465; doi:10.3390/molecules21111465 16. Dongmei Yang ME1, Qiushuang Wang ME1, LeqinKe BE1,2, Jianmei Jiang BE1 and Tiejin Ying PhD1, Antioxidant activities of various extracts of lotus (Nelumbo nuficeraGaertn) rhizome, Asia Pac J ClinNutr 2007;16 (Suppl 1):158-163 17. WeiLiu1Dan-DanYib1Jian-LiGuocZhuXingXiangcLin-FengDengdLeiHed , Nuciferine, extracted from NelumbonuciferaGaertn, inhibits tumor-promoting effect of nicotine involving Wnt/β-catenin signaling in non-small cell lung cancer, Journal of Ethnopharmacology, Volume 165, 13 May 2015, Pages 83-93

28



MARKET RESEARCH

Pfizer’s Medivation breast cancer PARP boosts PFS in phase 3 by: Ben Adams n experimental PARP med bought up as part of Pfizer’s multibillion-dollar Medivation buyout performed well in a latestage trial as the Big Pharma eyes regulatory filings. PARP became all the rage back in 2016 with some stellar data and a series of approvals, partially beating out other I-O and gene editing tech for column inches. The immediate win for Pfizer in its $14 billion deal to snap up Medivation was the blockbuster cancer drug Xtandi, but its pipeline was also a selling point; today, one of those later projects is looking as if it may come good. Talazoparib, originally a BioMarin drug before being sold to Medivation in 2015, is an oral, once-a-day PARP inhibitor being tested in the so-called EMBRACA study in a specific set of patients, namely those with germline (inherited) BRCA1/2-positive (gBRCA+) locally advanced and/or metastatic breast cancer (MBC). The data show superior progression-free survival (PFS) in patients treated with the drug when pitted against those who received chemo. Median PFS was 8.6 months for patients on talazoparib, while those on chemo saw 5.6 months. “This represents a 46% reduction in the risk of disease progression,” Pfizer said in a statement. The Big Pharma adds that the proportion of patients achieving a complete or partial response (known as an objective response rate) in the talazoparib group was more than twice that of the control arm (62.6% for talazoparib vs. 27.2% for chemo).

A

Pfizer says it will now “be discussing these data from EMBRACA […] with worldwide health authorities.” Pfizer will hope to get its med into an increasingly busy market that already has AstraZeneca’s Lynparza, Tesaro Zejula and Clovis’ Rubraca vying for position. And back in February, AstraZeneca rolled out phase 3 results showing that Lynparza could also top standard-of-care chemo at increasing progression-free survival in patients with HER2-negative breast cancer and BRCA1 or BRCA2 mutations. Game on for both (and with a hint of irony, given that Pfizer could have owned Lynparza if it had managed to buy AstraZeneca a few years back). Mace Rothenberg, M.D., chief development officer, Oncology, Pfizer Global Product Development, said: “Results from the EMBRACA study are very encouraging and a great example of precision drug development. By enrolling only patients with germline BRCA-positive metastatic breast cancer, treatment with talazoparib reduced the risk of disease worsening by nearly half, compared with current standard of care chemotherapy. This includes heavily pretreated patients, those with hormone receptor-positive disease and those who had a history of brain metastases.”

Story source/Credit: https://www.fiercebiotech.com

Roche's latest Tecentriq results shed little light on the lung cancer market race: analyst by Carly Helfand ore results may be out from a closely watched trial of Roche’s Tecentriq in lung cancer, but industry watchers still don’t have many of the answers they’re looking for. A phase 3 study combining the med with chemo—both with and without fellow Roche product Avastin—in the front-line setting yielded “some mixed findings,” as Bernstein analyst Tim Anderson put it in a Thursday afternoon note to clients.

M

30



MARKET RESEARCH One point he found “troubling”? A Tecentriq-chemo combo produced median overall survival of 17.9 months, while that pair plus Avastin put up a 19.3-month mark. Both those groupings topped an Avastin-chemo pairing, which posted a 14.4-month figure, but Avastin’s addition to the Tecentriqchemo cocktail—a 1.3-month addition—was “not impressive,” he wrote.

Pharmacy benefits managers (PBMs) and pharmacy operators with one of its oldest health insurers, whose national business ranges from employer healthcare to government plans.

Earnings per share by the low- to midsingle digit percentage points. Their vision expands beyond capitalizing on CVS` existing Minute Clinic structure, which largely offers

The deal comes after Aetna`s $37 billion plan to acquire smaller U.S. health insurance peer Humana Inc was blocked in January by a U.S. federal judge over antitrust concerns. A proposed combination of peers Anthem Inc and Cigna Corp was also shot down. Aetna shareholders stand to receive $207 per share in the deal with CVS, the companies said. The consideration comprises $145 per share in cash and 0.8378 CVS shares for each Aetna share. Reuters first reported the terms of the deal earlier on Sunday. Aetna shareholders will own about 22 percent of the combined company, while

preventative services like flu shots, the companies` chief executives said in an interview. "When you walk into CVS there`s the pharmacy. What if there`s a vision and audiology center, and perhaps a nutritionist, and some sort of care manager?" CVS CEO Larry Merlo said. Aetna will be operated as a separate unit and Aetna`s existing leadership is expected to run the Aetna businesses, Merlo said. Aetna will have two of its directors, in addition to Aetna CEO Mark Bertolini join the board of CVS. The deal comes as healthcare payers and pharmacies are responding to a shifting landscape, including changes in the Affordable Care Act, rising drug prices and the threat of competition from online retailers such as Amazon.com Inc. CVS plans to use its low-cost clinics to provide medical services to Aetna`s roughly 23 million medical members. Story Source/Credit: Zee Business

“Most clinicians would view this as too small of an efficacy benefit to justify what is arguably higher toxicity ... as well as a much higher cost,” he added. Adding Avastin to the Tecentriq-chemo duo increased the rate of adverse eventrelated discontinuations to 33% from 14%, Evercore ISI analyst Umer Raffat added in his own investor note. Story Source/Credit: Carly Helfand https://www.fiercepharma.com

CVS Health to acquire Aetna for $69 billion in year's largest acquisition he deal comes after Aetna`s $37 billion plan to acquire smaller U.S. health insurance peer Humana Inc was blocked in January by a U.S. federal judge over antitrust concerns. A proposed combination of peers Anthem Inc and Cigna Corp was also shot down. US drugstore chain operator CVS Health Corp said on Sunday it had agreed to acquire U.S. health insurer

T

Aetna Inc for $69 billion, seeking to tackle soaring healthcare spending through lower-cost medical services in pharmacies. This year`s largest corporate acquisition will combine one of the nation`s largest

CVS shareholders will own the remainder. The companies said that cost synergies in the second full year after the transaction closes -- 2020 if the deal closes in the second half of 2018 as they expect -- would amount to $750 million. They foresee it adding to adjusted

32



PRODUCT LAUNCH

Analytik Jena and BAM Agree to Cooperate in Research

T

he Bundesanstalt für Materialforschung und prüfung (Federal Institute for Materials Research and Testing, BAM) and

Analytik Jena AG have agreed to cooperate extensively in the research and development of optical spectrometry in the area of elemental analysis.

“Within the framework of our research activities, it is important to us to network closely with partners from the scientific and user community and to involve these partners early on in the process of developing and implementing ideas,” says Ulrich Krauss, CEO of Analytik Jena AG. “We want to develop marketable products from a knowledge and transfer network consisting of clients in collaboration with partners from research institutes.” BAM President Prof. Ulrich Panne elaborates: “We are pleased to be able to refine analysis using High-Resolution Continuum Source AAS (HR-CS AAS) technology in joint research with Analytik Jena AG. This approach also offers wide-ranging opportunities for our up-and-coming scientific talent.” Author/Story Source: Analytik Jena

The two parties signed a corresponding cooperation agreement last week in Berlin. The focus of the two partners’ future research efforts will be on the development of new devices and applications for element determination. In this connection, the teams will work jointly on the further development of the principles and methods of highresolution absorption spectrometry in order to determine ultratrace concentrations of atoms and molecules.

Lonza Announces New Offering of Silensomes™ HLM for Drug Metabolism Studies Author/source: Lonza

L

onza Walkersville announced its new offering of Silensomes™ Human Liver Microsomes (HLM) products – pooled human liver microsomes for in

vitro cytochrome P450 (CYP) phenotyping. CYP phenotyping is a regulatory requirement for new drug candidates to understand their metabolism and to predict drug-drug interactions. Lonza Walkersville's new Silensomes™ HLM products provide researchers a fully characterized pre-made solution for CYP phenotyping, resulting in more consistent and reliable results. Lonza's Silensomes™ HLM products include seven cryopreserved human liver microsomes pools that are each pretreated with a mechanistic-based inhibitor targeting a single CYP enzyme. This chemical inactivation is mechanism-based and irreversible, giving researchers confidence that their results are accurate and reliable. Each of the seven CYP Silensomes™ HLM are packaged as Silensomes™ CYP Phenotyping Kits to include a production-matched control microsome that was treated the same way without the inhibitor. A panel consisting of all seven Silensomes™ HLM with a single matched control is also available. This new product offering from Lonza is a result of the company's recent agreement with Biopredic International and strengthens Lonza's position as a leading supplier of ADME-Tox products for scientists working in drug development. The addition of


Silensomesâ„¢ HLM products expands


PRODUCT LAUNCH Lonza's extensive ADME-Tox portfolio, which includes fresh and cryopreserved human and animal primary hepatocytes, specialized media and cell culture systems. "With regulatory authorities specifying CYP phenotyping as part of the drug development process, we wanted to support scientists working in this area by offering more-reliable and easier-to-use models," said Maureen Bunger, Product Manager for ADME-Tox Solutions at Lonza. "Our Silensomes™ HLM products are supplied in a ready-to-use format and provide a single in vitro

“Life science researchers are under pressure to deliver innovative and reproducible results at an ever-increasing

Solution for CYP phenotyping, helping to simplify drug metabolism studies for researchers." Silensomes™ HLM products are produced by and are a trademark of Biopredic International. Story source: Lonza

Merck Introduces Stericup® Quick Release System for Improved Cell Culture Filtration Author/source: Merck erck, a leading science and technology company, has launched the new Stericup® Quick Release 500 ml vacuum filtration system, a filter bottle system ideally suited for sterile filtration of cell culture media, buffers and reagents. The Stericup® Quick Release system is the next generation of the original Stericup® Sterile Vacuum Filtration System, which has been a staple in labs around the world for decades. The improved liquid sterile filtration system offers ergonomic design updates that optimize user control and streamline the filtration process, while safeguarding results with the proven performance of Millipore® membranes.

M

Pace and with greater returns. Even seemingly routine processes like microfiltration must be reliable and consistent, because quality and reproducibility are critical to the cell culture process,” said Klaus Bischoff, Head of the Research Solutions business, Life Science, at Merck. Merck’s Stericup® Quick Release system not only mitigates inherent pain points experienced by scientists during sterile filtration, like concerns over maintaining sterility and spillage, but also streamlines the overall process while establishing a foundation for reliability, consistency and confidence for steps downstream. Story source: Merck

New Avanti J-15 Series Centrifuges Redefine Beckman Coulter’s Portfolio Author/source: Beckman Coulter

elebrating 70 years as a world leading manufacturer of laboratory centrifuges, Beckman Coulter Life Sciences introduces the next generation of refrigerated, high-speed benchtops—the Avanti J-15 Series. Designed to leverage harmonic technology that ensures ultra-smooth acceleration/deceleration profiles, the Avanti J-15 Series protects samples from disturbance so scientists can get larger soft pellets and higher sample yield from each run. This technology also helps improve operational efficiency, which can save time by shortening workflows. “The new Avanti J-15 Series addresses the two most important factors in any experiment: time spent performing it and how much you get out of it,” says Julia Luciano-Chadee, senior applications scientist with Beckman Coulter. “We designed this new benchtop to save time while increasing yield. For experiments that require multiple short runs, we’ve seen up to a 10% reduction in the time required for completion. For

C

busy, high-use labs, that time savings can add up over the course of a workweek. It also helps maintain sample integrity, because they can be spun sooner rather than sitting—often on ice—waiting to be processed.” The Avanti J-15 Series was designed to deliver repeatable results for a variety of applications—including cell culturing; “spinfection” to improve transduction; nucleic acid purification; protein concentration; blood processing and assay setup. This versatility means it can effectively replace four of Beckman Coulter’s Allegra refrigerated benchtop models. The Avanti J-15 Series utilizes the same consumable offering including adapters, tubes, bottles, and Aerosolve canisters as the Allegra models (X-12, X14, and X-15)†. Another important enhancement is multi-dimensional imbalance tolerance (MIT), which is enabled by improvements in instrument design combined with a new software algorithm. MIT can help identify

36



PRODUCT LAUNCH imbalances more quickly and accurately, thereby reducing the chance of a “false positive” imbalance alert, so researchers can “set it and forget it” with confidence. The high-contrast “app-like” design of the Avanti J-15 software interface will look familiar to anyone who uses the latest smartphone or tablet, and enables fast, easy access to up to 99 customizable programs. Beckman Coulter’s design engineers have even made sure the touchscreen is

sufficiently sensitive to gloved fingertips, for maximum user convenience protection. Author/source: Beckman Coulter

and

Expanding Applications for Temperature/Hu midity Controlled Stability Chambers Author/source: SP Scientific Inc. SP Scientific reports upon the growing range of applications served by its premium Hotpack Stability Chambers. Available in a variety of customizable models, these systems provide precision temperature control from 2°C to 70°C and 20% to 96%RH with exceptional

uniformity throughout the chamber and therefore can serve a diverse array of applications across a multitude of industries. Hotpack Stability Chambers are used in the pharmaceutical, automotive, and Cosmetic industries to test the resilience of product samples under controlled temperature and humidity variables. Hotpack Stability Chambers are also used to test packaged food in sealed bags for moisture permeability. A leading national naval laboratory relies on Hotpack Stability Chambers to house its atomic clocks. Concrete and drywall manufacturers also use Hotpack Stability Chambers for their product testing. The Model 33R is a highquality temperature/humidity controlled Stability Chamber, built to exceed the exacting standards required by such regulatory bodies as ICH, TAPPI, and MIL Spec. This Stability Chamber is constructed from 304 Stainless Steel and finished with an external protective finish. Each unit is equipped with four solid stainless-steel shelves secured by pilasters designed to bear substantial test loads. High density testing is accommodated by up to 19 available shelf positions .Outstanding accuracy and optimal performance on the Model 33R is achieved by a microprocessor-based PID controller which regulates usersettable temperature and humidity limits. An audio-visual alarm system is available to alert users to events such as power interruptions that may disturb test results. The proprietary Stability PLUS™ design of the Model 33R

Stability Chamber. SP Scientific is a leading manufacturer of controlled environmental rooms and chambers, freeze dryers / lyophilizers, aseptic vial washing and tray loading machines, temperature control / thermal management, centrifugal evaporators and concentrators, and glassware washers. The company sells its products

through its reputable line of brands including Hotpack, Hull, PennTech, VirTis, FTS Systems, and Genevac. SP Scientific has ISO 9001:2008 registered production facilities in the USA and Europe. Story Source: SP Scientific Inc.

Imaseal® - Silicone Inflatable Seals and Gaskets Imaseal® is made from advance grade silicone rubber conforms to FDA 21 CFR 177.2600 for food grade criteria suitable for various sealing applications

provides the gentle, even flow of conditioned air which ensures precision testing without the risk of temperature variations or inadvertent evaporation of samples. A comprehensive array of accessory options including access ports, PC interfaces, and chart recorders are available for this temperature controlled

38



PRODUCT LAUNCH

These inflatable seals starts inflation range from 5mm to 20mm when 2-4 kg.

/cm2 pressure is applied after installation in door. Imaseal® is certified by Food Grade Certificate (Conforms to FDA 21 CFR), Laboratory Test Report, TSE/BSE Free Certificate and Phthalate Free Certificate. Imaseal®is used in Fluid Bed Dryers/Processors/Coaters, Autoclaves, Sterilizers, Isolators, Glove Box, Furnaces, Rapid Mixer Granulators, Nuclear Door Seals, Robotics & Fluid

Sealing, Airlock Door Seals, Powder & Bulk Solid Handling Machineries, Electronic/Wafer Semiconductor Processing, etc.

Ami Polymer Pvt. Ltd. 319, Mahesh Industrial Estate, Opp. Silver Park, Mira-Bhayander Road, Mira Road (E), Thane - 401104, Maharashtra. INDIA Tel.: +91 22 28555 107 / 631 / 914 | Cell: +91 86910 13935 Email: mktg@amipolymer.com | Web: www.amipolymer.com





14th to 16th December 2017

Nepal

26th Feb to 1st March 2018

USA

16th to 18th March 2018

23rd to 25th February 2018

Hyderabad

5th to 8th February 2018

Dubai, UAE

21st to 23rd April 2018

19th to 21st April 2018

China

Chennai

2nd to 4th April 2018

Singapore

11th to 15th June 2018

Germany

21st to 23rd September

Delhi

5th to 7th September 2018

Cambodia

14th to 16th December 2018

Myanmar





RNI NUMBER: UPENG/2017/73675


Turn static files into dynamic content formats.

Create a flipbook
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.